Vaccine Safety Debates: Understanding Side Effects and Public Health in Bangladesh

When the Debate Became Louder Than the Science

In the summer of 2021, a headline circulated widely across social media in Bangladesh: more vaccinated people were dying of COVID-19 in England than unvaccinated ones. The claim spread through Facebook groups, WhatsApp chains, and community gatherings. What few readers understood was the statistical phenomenon behind it — Simpson's Paradox — which occurs when a trend in aggregated data reverses when the data is broken into subgroups. In England, the vaccinated population was overwhelmingly older and more vulnerable; of course more of them died in absolute numbers. But the rate of death among the unvaccinated was dramatically higher. The headline was technically accurate and deeply misleading at the same time.

That single piece of misinformation, amplified across South Asia, shaped how millions of Bangladeshis thought about vaccine safety at a critical moment in the country's immunization drive. Understanding what actually happened — both in terms of real side effects and manufactured fear — matters not just as history, but as preparation for the next public health emergency.

Bangladesh's COVID Vaccination Campaign: The Numbers

Bangladesh received its first COVID-19 vaccine on February 7, 2021 — a shipment of Covishield produced by the Serum Institute of India under AstraZeneca's licence. The rollout began with frontline healthcare workers and the elderly, and the country ultimately deployed six of the eight WHO-approved vaccines: Moderna, Pfizer, Covishield, Sinopharm, Sinovac, and Janssen. By mid-2023, Bangladesh had administered over 140 million doses to a population of approximately 170 million — a logistical achievement that few predicted for a country with the population density of Dhaka and the healthcare infrastructure gaps of rural Sylhet or Rangpur.

The supply chain was never smooth. In April 2021, India imposed an export ban on Covishield amid a devastating second wave, leaving Bangladesh's vaccination programme temporarily stalled. The government pivoted quickly, securing Sinopharm doses from China and Moderna through the COVAX facility. That diversification — born of necessity — would later become a data asset: Bangladeshi researchers now have a rare multi-vaccine dataset to study comparative side effect profiles within a single South Asian population.

What the Side Effect Data Actually Shows

The most comprehensive study to emerge from Bangladesh's vaccination drive was published in Scientific Reports in 2025 by researchers from Bangabandhu Sheikh Mujib Medical University (BSMMU) in Dhaka. The study tracked 2,534 subjects who had received two doses of Pfizer, Moderna, AstraZeneca, or Sinopharm vaccines, following them within seven days and up to 28 days after each dose. The findings were consistent with global data: adverse effects were predominantly mild to moderate — injection site pain, fever, fatigue, and headache — and resolved without medical intervention in the vast majority of cases.

A separate cross-sectional study published in Frontiers in Public Health in 2024 surveyed 1,180 vaccinated Bangladeshis and found that fewer than 40 percent — specifically 39.48 percent — reported experiencing at least one side effect after vaccination. Among those who did, the side effects were transient. The Bangladesh Pharmaceutical Journal published research in 2024 specifically examining COVID vaccine effects on menstrual cycles, surveying 309 women. Of these, 210 reported vaccine-associated side effects, with fever as the most common complaint. The study found no significant conclusive negative effect on menstrual health, though it documented temporary cycle irregularities in a subset of respondents — findings that, when stripped of context, fuelled considerable anxiety online.

The AstraZeneca vaccine drew the most scrutiny globally. Vaccine-Induced Thrombocytopenia and Thrombosis (VITT), a rare clotting disorder, occurred at a rate of approximately one in every 100,000 doses. AstraZeneca voluntarily withdrew its COVID-19 vaccine from global markets in May 2024, citing a commercial environment where updated mRNA variants had largely superseded it. The withdrawal was not a safety recall — the vaccine had by then completed its primary role in the pandemic response — but the headlines it generated reignited safety anxieties in Bangladesh long after the mass vaccination phase had concluded.

The Misinformation Problem Was Real and Local

The WHO's Bangladesh office flagged the infodemic as a parallel emergency to the pandemic itself. Religious anxieties played a role: rumours circulated in some communities that vaccines contained pork-derived gelatin, rendering them haram, a claim that Islamic scholars and the government both refuted. More damaging were Facebook pages spreading screenshots of unverified death reports and decontextualised data from Western countries. The algorithm's preference for emotionally charged content meant fear travelled faster than fact.

The government's response included enlisting local imams to deliver pro-vaccination messages during Friday prayers, a grassroots strategy that proved more effective in rural areas than national television campaigns. Community health workers — the backbone of Bangladesh's Expanded Programme on Immunization since 1979 — were redeployed to address vaccine hesitancy door-to-door in districts where uptake lagged. The strategy worked unevenly. Urban centres in Dhaka and Chittagong hit their targets. In some coastal and haor regions, convincing families required repeated visits and the visible participation of respected local figures.

Bangladesh's Immunization Foundation: Older and Deeper Than COVID

The COVID vaccination drive did not happen in a vacuum. Bangladesh's Expanded Programme on Immunization, established in 1979, is one of the most successful public health achievements in the country's history. By 2023, WHO/UNICEF data showed childhood vaccination coverage for core antigens exceeding 95 percent — a figure that places Bangladesh ahead of many middle-income countries and reflects decades of investment in community health infrastructure.

That foundation mattered enormously during COVID. The community health worker network, the cold chain logistics, the district-level immunization tracking systems — all of it was repurposed and scaled. Bangladesh did not build its COVID vaccination infrastructure from scratch; it expanded one that already existed. The contrast with countries that had to construct vaccine delivery systems mid-pandemic was stark and instructive.

The National Immunization Strategy 2023–2027 now includes a specific focus on pharmacovigilance — systematic monitoring of adverse events following immunization. This is a direct lesson from COVID: Bangladesh needs not only the ability to deliver vaccines at scale, but the institutional capacity to monitor, investigate, and communicate safety signals in real time, before misinformation fills the void.

The Healthcare Infrastructure Gap That Remains

Bangladesh's vaccination success exists alongside a healthcare system that remains critically under-resourced at the secondary and tertiary levels. The country has fewer than one critical care bed per 10,000 people. District hospitals outside major cities frequently lack the diagnostic equipment to identify vaccine-related adverse events with precision — which means that when unusual symptoms appear after vaccination, they are sometimes attributed to the vaccine by default, not by evidence.

In February 2024, a troubling cluster of unidentified deaths was reported in Rajshahi — two young sisters, aged two and five, who died from an illness that local health authorities could not immediately classify. The case, documented in a 2025 study published in Public Health Challenges, highlighted how Bangladesh's diagnostic gaps create conditions where genuine public health signals can be missed, and where unrelated events can be incorrectly linked to vaccines or other interventions in the absence of clear answers. The Rajshahi case was ultimately not vaccine-related, but it underscored the fragility of public trust when the healthcare system cannot explain what it is seeing.

What the Debate Revealed About Future Preparedness

Bangladesh's COVID vaccine experience produced three clear lessons that apply directly to the next health emergency — whether that is Disease X, a new influenza variant, or a pathogen that does not yet have a name.

The first is pharmacovigilance. Bangladesh must invest in real-time adverse event surveillance infrastructure — not just the ability to collect reports, but the laboratory capacity to investigate them, the epidemiologists to analyse patterns, and the communications infrastructure to report findings publicly before rumours take hold. The National Immunization Strategy's focus on pharmacovigilance is the right instinct; the question is whether the funding and institutional follow-through will match the stated ambition.

The second is supply sovereignty. The April 2021 Indian export ban on Covishield exposed how dependent Bangladesh was on a single bilateral supply arrangement. The subsequent diversification to Chinese Sinopharm and COVAX-sourced Moderna was reactive, not planned. A true pandemic preparedness framework would include pre-negotiated multi-source procurement agreements, regional vaccine manufacturing capacity — potentially through SAARC frameworks — and domestic formulation capacity that does not yet exist at meaningful scale.

The third is the misinformation infrastructure. Bangladesh cannot address vaccine hesitancy purely through counter-messaging at the moment of crisis. The institutional relationships — with religious leaders, with community health workers, with local journalists, with trusted figures in conservative communities — need to be built during peacetime, not assembled in a panic when the next outbreak arrives. The imam network that was mobilised during COVID existed because of decades of prior community health engagement. That network needs to be maintained, not demobilised once the immediate emergency passes.

The scientific consensus on COVID-19 vaccine safety is unambiguous: the vaccines were safe, effective, and collectively responsible for preventing millions of deaths globally. In Bangladesh, they helped a country of 170 million people navigate a pandemic with a healthcare system that was not designed for that scale of stress. The side effects were real, predominantly mild, and vastly outweighed by the benefits. The debate about them was also real — and understanding why that debate was so difficult to win is as important as understanding the vaccines themselves.

win-tk.org is a wintk publication covering Bangladesh and global affairs for English and Bengali-speaking readers worldwide.